The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels
Open accessAbstract
Purpose: To report on the long-term results of a randomized trial comparing a standard dose (400 mg/d) versus a higher dose (800 mg/d) of imatinib in patients with metastatic or locally advanced GI stromal tumors (GISTs). Patients and Methods: Eligible patients with advanced CD117-positive GIST from 56 institutions in 13 countries were randomly assigned to receive either imatinib 400 mg or 800 mg daily. Patients on the 400-mg arm were allowed to cross over to 800 mg upon progression. Results: Between February 2001 and February 2002, 946 patients were accrued. Median age was 60 years (range, 18 to 91 years). Median follow-up time was 10.9 years. Median progression-free survival times were 1.7 and 2.0 years in the 400- and 800-mg arms, respectively (hazard ratio, 0.91; P = .18), and median overall survival time was 3.9 years in both treatment arms. The estimated 10-year progression-free survival rates were 9.5% and 9.2% for the 400- and 800-mg arms, respectively, and the estimated 10-year overall survival rates were 19.4% and 21.5%, respectively. At multivariable analysis, age (< 60 years), performance status (0 v ≥ 1), size of the largest lesion (smaller), and KIT mutation (exon 11) were significant prognostic factors for the probability of surviving beyond 10 years. Conclusion: This trial was carried out on a worldwide intergroup basis, at the beginning of the learning curve of the use of imatinib, in a large population of patients with advanced GIST. With a long follow-up, 6% of patients are long-term progression free and 13% are survivors. Among clinical prognostic factors, only performance status, KIT mutation, and size of largest lesion predicted long-term outcome, likely pointing to a lower burden of disease. Genomic and/or immune profiling could help understand long-term survivorship. Addressing secondary resistance remains a therapeutic challenge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Nilsson, B., Bümming, P., Meis‐Kindblom, J. M., Odén, A., Dortok, A., Gustavsson, B., Sablinska, K., & Kindblom, L. (2005) · Cancer · doi:10.1002/cncr.20862 · Cited by 1,272
Cited by
Gastrointestinal stromal tumours
Blay, J.-Y., Kang, Y.-K., Nishida, T., & von Mehren, M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00254-5 · Cited by 460
Self-citationBlay, J.-Y., Serrano, C., Heinrich, M. C., Zalcberg, J., Bauer, S., Gelderblom, H., Schöffski, P., Jones, R. L., Attia, S., D'Amato, G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30168-6 · Cited by 416
Self-citationHeinrich, M. C., Jones, R. L., von Mehren, M., Schöffski, P., Serrano, C., Kang, Y.-K., Cassier, P. A., Mir, O., Eskens, F., Tap, W. D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30269-2 · Cited by 320
Self-citationGastrointestinal Stromal Tumors
von Mehren, M., & Joensuu, H. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.9705 · Cited by 306
Targeting tumour microenvironment by tyrosine kinase inhibitor
Tan, H.-Y., Wang, N., Lam, W., Guo, W., Feng, Y., & Cheng, Y.-C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0800-6 · Cited by 107
Metadata
- Authors
- Casali, P. G., Zalcberg, J., Le Cesne, A., Reichardt, P., Blay, J.-Y., Lindner, L. H., Judson, I. R., Schöffski, P., Leyvraz, S., Italiano, A., Grünwald, V., Pousa, A. L., Kotasek, D., Sleijfer, S., Kerst, J. M., Rutkowski, P., Fumagalli, E., Hogendoorn, P., Litière, S., Marreaud, S., van der Graaf, W., Gronchi, A., Verweij, J., & on behalf of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, I. S. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-05-20
- Volume
- 35
- Issue
- 15
- Pages
- 1713-1720
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2601222128
- Cited by
- 194
- References
- 2
- FWCI
- 15.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.